let’s talk lyme vaccine—when i fist started following this company covid wasn’t even a thing.
how do we feel about the potential sales for that one…and anything else interesting in the pipeline (tired of the covid vaccine drama…need a new topic of conversation!)
J
losing the EU deal us very bad news.
D
200% Gross, Growth rate compared to last year for their existing vaccine products Breakdown ttm 12/31/2021 12/31/2020 12/31/2019 12/31/2018 Total Revenue 348,085 348,085 110,321 126,196 113,035 Cost of Revenue 187,920 187,920 54,302 49,968 43,431 Gross Profit 160,165 160,165 56,019 76,228 69,604
t
Valneva beyond Covid 1. Ixiaro & Dukoral - both marketed vaccines will gain momentum again as the travel market recovers. Before Covid they had combined sales of >100 m (US Army has a major multi-year contract) 2. Chikungunya - most likely, a lot of militaries will buy this vaccine - peak sales can reach ~ 500 m. Not to forget, as Valneva will very likely be the first company to bring such a vaccine to the market, they will be eligible for a priority review voucher worth 80-100 m. 3. Borellia - here the P 3 is expected to start in Q3 2022, peak sales clearly beyond 1 bn as this is a raising healthcare threat. 4. Valneva will hopefully bring more assets into the clinic in the next 12-24 months
D
Duh, Lets go VALN and ingredient maker DVAX. Buh by Big Pharma shorties with their Toxic Vaccines
Valneva says the European Medicines Agency accepted application for its COVID-19 vaccine
U.S.-listed shares of Valneva SE jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its COVID-19 vaccine candidate. If the experimental shot receives a positive recommendation from the EMA's Committee for Human Medicinal Products, the company said it expects a decision in June. The European Commission then decides whether to authorize the vaccine. Valneva's vaccine is an inactivated, whole-virus shot that was te
Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial GlobeNewswire COVID-19 Boosters: The Latest Advice Eat This, Not That!
AdDaily Stock Buzz 3 Superstar Stocks to Buy Right Now (Free Report)
Discover 3 low-priced stocks to buy now, including our #1 growth stock for 2022. You'll find their names in this free Special Report GlobeNewswire•14 hours ago EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
Saint Herblain (France), May 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization application (MAA) for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001. Acceptance of the MAA means VLA2001 is advancing from the rolling review process and beginning the formal review process by the EMA’s Committee for Human Medicinal Products (CHM
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing CNW Group Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial GlobeNewswire
M
Zacks Rank & Stock to Consider
Valnevacurrently carries a Zacks Rank #4 (Sell). Zacks Equity Research Tue, May 17, 2022, 2:10 PM
g
Guys Check it out oil PED. Earnings is after hour will be exploded.
M
In order to build your wealth you have to invest. Investing is the ability which allows you to put your money in vehicle that have the potential to earn strong rate of return.
M
I was not acting dishonestly. I said strong sell at 16 euros. Not at 10 euros like Zack. He gave it a better rating before that. Only a deal that is now uncertain can't change a company's valuation that much.
t
I do not think that Valneva is marketing the smallpox vaccine as there is absolutely no private market, but only contracts with governments and I assume that this will be done by Bavarian Nordic itself
S
The current EU supply agreement is worth around 1 billion euro to Valneva...would that be correct? While their total market cap is only 1.5B euro. Looks like another covid wave could be incoming...if the EU approves this in April just as another wave hits then that could be extra bullish for price. Whatever about the long term success of this (and you could make a moderately bullish argument for that now that the jab has been validated by the UK health health authority) it could be worth throwing down at this price as a purely short term speculative play. I'm in (again), let's go!
M
Money becomes more expensive. No profits, only share sales. No dividend. What is the point of buying this stock?
J
You should be happy the stock is only down 20% premarket. That is a gift. Should be down 45 or 50%
M
I told you Strong sell ! last month, check it out
J
think this will slowly creep back up. Europe has big deal with valneva. just dragging their feet a bit over approval. I Neen 15 to break even. would sell if it gets back to 19
D
Marcello reply to bos own devious posts. look it up. this #$%$ has decent #s, potential, lots of cash and the drop in price from manipulation is staggering. when most bought this stock it had all ten anylist saying "Strong Buy"??. promoted by Robinhood to fleece young investors. I know this as I opened an account back then just to see how it works.This shorting should be investigated. Big Pharma Shorters?Any one interested?
D
VALN, is the best and safest Vaccine. No spike proteins and other graphic metal bio blades trash and nanobots etc. like MRNA and PFE Vaccines don't work and harm people.
M
I told you not to buy
J
no one seems to bother with this board unless there's bad news. I'm hoping for good news soon from EMA and we keep the Europe deal.
https://valneva.com/press-release/valneva-and-bavarian-nordic-announce-marketing-and-distribution-partnership/
THEN READ;
https://www.bavarian-nordic.com/investor/news/news.aspx?news=6574
how do we feel about the potential sales for that one…and anything else interesting in the pipeline (tired of the covid vaccine drama…need a new topic of conversation!)
Breakdown
ttm
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Revenue
348,085
348,085
110,321
126,196
113,035
Cost of Revenue
187,920
187,920
54,302
49,968
43,431
Gross Profit
160,165
160,165
56,019
76,228
69,604
1. Ixiaro & Dukoral - both marketed vaccines will gain momentum again as the travel market recovers. Before Covid they had combined sales of >100 m (US Army has a major multi-year contract)
2. Chikungunya - most likely, a lot of militaries will buy this vaccine - peak sales can reach ~ 500 m. Not to forget, as Valneva will very likely be the first company to bring such a vaccine to the market, they will be eligible for a priority review voucher worth 80-100 m.
3. Borellia - here the P 3 is expected to start in Q3 2022, peak sales clearly beyond 1 bn as this is a raising healthcare threat.
4. Valneva will hopefully bring more assets into the clinic in the next 12-24 months
Valneva says the European Medicines Agency accepted application for its COVID-19 vaccine
U.S.-listed shares of Valneva SE jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its COVID-19 vaccine candidate. If the experimental shot receives a positive recommendation from the EMA's Committee for Human Medicinal Products, the company said it expects a decision in June. The European Commission then decides whether to authorize the vaccine. Valneva's vaccine is an inactivated, whole-virus shot that was te
Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial
GlobeNewswire
COVID-19 Boosters: The Latest Advice
Eat This, Not That!
AdDaily Stock Buzz
3 Superstar Stocks to Buy Right Now (Free Report)
Discover 3 low-priced stocks to buy now, including our #1 growth stock for 2022. You'll find their names in this free Special Report
GlobeNewswire•14 hours ago
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
Saint Herblain (France), May 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization application (MAA) for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001. Acceptance of the MAA means VLA2001 is advancing from the rolling review process and beginning the formal review process by the EMA’s Committee for Human Medicinal Products (CHM
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
CNW Group
Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial
GlobeNewswire
Valnevacurrently carries a Zacks Rank #4 (Sell).
Zacks Equity Research
Tue, May 17, 2022, 2:10 PM
I said strong sell at 16 euros.
Not at 10 euros like Zack.
He gave it a better rating before that.
Only a deal that is now uncertain can't change a company's valuation that much.
No profits, only share sales.
No dividend.
What is the point of buying this stock?